To: John Pitera who wrote (3590 ) 3/27/2001 9:15:19 AM From: John Pitera Read Replies (2) | Respond to HGSI is expanding it's strategic relationship with Takeda chemicals of Japan in a drug discovery alliance. I think that this is one of the areas where we shall see Japan Blossom over the next 3 to 5 years. 100 targets for use in small molecule and antibody drug discovery. Takeda because of their relevance to several of the therapeutic areas in which Takeda is focused, such as diabetes, cardiovascular diseases, bone and joint diseases, central nervous system disorders, urogenital diseases and allergy. Takeda, the largest pharmaceutical company in Japan, is one of Human Genome Sciences' five strategic partners in its human gene consortium . Through the 1995 agreement with Human Genome Sciences, Takeda became one of the world's first major pharmaceutical companies, and the first in Japan, to enter into a broad strategic alliance in order to access state-of-the-art genomics information and technology.so many targets of interest for their own drug discovery efforts . We have a high regard for Takeda's research capabilities and view the selection of these targets as a further strengthening of our long term relationship.''Takeda Chemicals, the largest pharmaceutical company in Japan, recorded pharmaceutical sales of U.S. $6.4 billion in fiscal year 1999. hgsi.com . Copies of HGS press releases are also available by fax 24 hours a day at no charge by calling 800-758-5804, ext. 121115
